« Back to Medicines list

Daxas 500 mcg Film-coated Tablets

  • Name:

    Daxas 500 mcg Film-coated Tablets

  • Company:
    info
  • Active Ingredients:

    roflumilast

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 11/09/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 11/9/2020
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

AstraZeneca Pharmaceuticals (Ireland) DAC

AstraZeneca Pharmaceuticals (Ireland) DAC

Company Products

Medicine NameActive Ingredients
Medicine Name Arimidex Active Ingredients Anastrozole
Medicine Name Bricanyl Turbohaler Active Ingredients Terbutaline sulfate
Medicine Name Brilique 60 mg film-coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg film coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg Orodispersible Tablets Active Ingredients Ticagrelor
Medicine Name Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen Active Ingredients Exenatide
Medicine Name Casodex 50mg Film-coated Tablets Active Ingredients Bicalutamide
Medicine Name Crestor 5 mg, 10 mg, 20 mg and 40 mg Tablets Active Ingredients Rosuvastatin Calcium
Medicine Name Daxas 250 mcg Film-Coated Tablets Active Ingredients roflumilast
Medicine Name Daxas 500 mcg Film-coated Tablets Active Ingredients roflumilast
Medicine Name Fasenra 30 mg solution for injection in pre filled syringe Active Ingredients Benralizumab
Medicine Name Fasenra 30 mg solution for injection in pre-filled pen Active Ingredients Benralizumab
Medicine Name Faslodex Active Ingredients Fulvestrant
Medicine Name Fluenz Tetra nasal spray suspension Active Ingredients Influenza vaccine (live attenuated, nasal)
Medicine Name Forxiga 10 mg Film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name Forxiga 5 mg film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name IMFINZI 50 mg/mL concentrate for solution for infusion Active Ingredients durvalumab
Medicine Name IRESSA 250 mg film-coated tablets Active Ingredients gefitinib
Medicine Name Komboglyze 2.5mg-1000mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Komboglyze 2.5mg-850mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Lokelma 10 g powder for oral suspension Active Ingredients Sodium Zirconium Cyclosilicate
Medicine Name Losec MUPS 10mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
Medicine Name Losec MUPS 20mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
Medicine Name Losec MUPS 40mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
Medicine Name Lynparza 100 mg and 150 mg Film-Coated Tablets Active Ingredients Olaparib
1 - 0 of 47 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 11 September 2020 SPC

Reasons for updating

  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 September 2020 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 4 June 2020 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 4 June 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 24 April 2020 SPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 23 January 2020 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 23 January 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 28 June 2019 SPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 27 May 2018 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 4 May 2018 PIL

Reasons for updating

  • Change to section 3 - dose and frequency
  • Change to section 6 - date of revision

Updated on 4 May 2018 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 6 December 2016 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 7: MA holder has been updated with AstraZeneca Ltd details

Section 8: New MA number

Section 10: Date of revision of the text

Updated on 6 December 2016 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 December 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 December 2016 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number

Updated on 1 March 2016 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
  • In section 4.4, information on body weight <60 kg has been added
  • In section 4.8, information on undesirable effects in other special populations and concomitant treatment with long acting muscarinic receptors (LAMA) has been added.
  • In section 5.1, data on clinical efficacy associated with Study RO-2455-404-RD has been added
  • In section 5.2, data on pharmacokinetic properties in special populations has been added.
  • Date of revision has been updated to 17 December 2015

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The SmPC has been updated as a result of approval of a Type II variation to update the SmPC with data associated with the REACT study.

  • In section 4.4, information on body weight <60 kg has been added
  • In section 4.8, information on undesirable effects in other special populations and concomitant treatment with long acting muscarinic receptors (LAMA) has been added.
  • In section 5.1, data on clinical efficacy associated with Study RO-2455-404-RD has been added
  • In section 5.2, data on pharmacokinetic properties in special populations has been added.
  • Date of revision has been updated to 17 December 2015

Updated on 12 May 2015 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to section

Details of change

4.2. Posology and method of administration

Posology

The recommended dose is one tablet of 500 micrograms (one tablet) roflumilast once daily.

 

Special populations

Older peopleElderly (65 years and older)

4.4.  Special warnings and precautions for use

 

Rescue medicinal products

Roflumilast Daxas is an anti-inflammatory substance indicated for maintenance treatment of severe COPD associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment. It is not indicated as rescue medicinal product for the relief of acute bronchospasms.

 

NOTE: ‘Daxas’ is now referred to as ‘roflumilast’ throughout the rest of the document.

 

4.8. Undesirable Effects

‘Panic attack’ has been added as a ‘Rare’  ‘Psychiatric disorder’.

5.1. Pharmacodynamic properties

Mechanism of action

Roflumilast is a PDE4 inhibitor, a non- steroid, anti- inflammatory agent active substance designed to target both the systemic and pulmonary inflammation associated with COPD.

6.1.  List of excipients

Coating

Hypromellose 2910

10. DATE OF REVISION OF THE TEXT

 

Changed to:

24th April 2015

Updated on 12 May 2015 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 18 September 2013 PIL

Reasons for updating

  • Change to side-effects

Updated on 10 September 2013 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 9 September 2013 SPC

Reasons for updating

  • Addition of black triangle
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

 

In Section 4.8 – Undesirable effects, the following wording has been added:

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to Pharmacovigilance Section, Irish Medicines Board, Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, IRL – Dublin 2. Tel: +353 1 6764971, Fax: +353 1 6767836, Website: www.imb.ie. e-mail:imbpharmacovigilance@imb.ie.

Updated on 16 April 2013 SPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Additon of Angioedema to section 4.8

Updated on 16 April 2013 PIL

Reasons for updating

  • Change to side-effects

Updated on 20 February 2013 PIL

Reasons for updating

  • Change to date of revision

Updated on 2 January 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 2 January 2013 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Marketing Authorisation Holder has changed to Takeda GmbH
Date of the revision of text has changed to 30/11/2012

Updated on 12 November 2012 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Addition of warnings regarding Psychiatric effects to sections 4.4 and 4.8 of the SmPC.

Updated on 6 November 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 20 April 2012 PIL

Reasons for updating

  • Change to further information section

Updated on 14 July 2011 SPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Addition of calendar pack and corresponding changes to pack sizes listed in the SmPC.

Updated on 13 September 2010 PIL

Reasons for updating

  • Change to further information section

Updated on 13 August 2010 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 12 August 2010 PIL

Reasons for updating

  • New PIL for new product